Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, Pfizer in Toxicogenomics Deal

NEW YORK, Jan. 7-CuraGen is working with Pfizer to apply toxicogenomics screening and protein pathway mapping for the pharmaceutical company's drug candidates, CuraGen said today.


CuraGen researchers will use the company's Predictive Toxicogenomics Screen early on in the drug development process to select promising compounds. The company will also supply its protein pathway mapping techniques to explore mechanisms and activity of drugs in later development stages.


Financial details of the agreement were not disclosed.


For further information, see the press release.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.